Axsome's Auvelity Wins FDA Nod

What Is Agitation in Alzheimer's Disease and Why Is It So Difficult to Treat?

Agitation in Alzheimer's dementia describes a cluster of behaviors including verbal outbursts, physical aggression, pacing, and emotional lability that emerge as neurodegeneration progresses. According to the Alzheimer's Association, neuropsychiatric symptoms affect the majority of patients at some point during their illness, and agitation is among the most distressing for both patients and caregivers. These behaviors frequently precipitate nursing home placement and contribute substantially to caregiver burnout.

For decades, clinicians treated dementia-related agitation off-label with atypical antipsychotics such as risperidone, olanzapine, and quetiapine. However, the FDA placed a black box warning on these medications in 2005 after analyses showed increased mortality risk in elderly patients with dementia. This created a long-standing therapeutic vacuum, with families and physicians forced to weigh modest behavioral benefits against documented risks of stroke, falls, sedation, and death.

How Does Auvelity Work and What Did the Clinical Trials Show?

Auvelity (AXS-05) pairs dextromethorphan — best known as a cough suppressant — with bupropion, an established antidepressant. The combination is pharmacologically clever: bupropion inhibits the CYP2D6 enzyme that normally rapidly metabolizes dextromethorphan, allowing therapeutic levels to accumulate. Dextromethorphan acts as an uncompetitive NMDA receptor antagonist and sigma-1 receptor agonist, modulating glutamatergic neurotransmission implicated in mood and behavioral regulation.

Axsome's ADVANCE clinical program evaluated the drug in patients with probable Alzheimer's disease and clinically significant agitation. According to data the company reported during regulatory review, treatment produced statistically significant reductions in agitation scores compared with placebo, measured by the Cohen-Mansfield Agitation Inventory. The safety profile compared favorably with antipsychotic alternatives, without the cardiometabolic and cerebrovascular concerns that have constrained off-label antipsychotic use in this population.

What Does This Approval Mean for Patients, Caregivers, and the Alzheimer's Treatment Landscape?

Auvelity becomes only the second drug ever specifically approved by the FDA for agitation in Alzheimer's dementia, joining brexpiprazole (Rexulti), which received this indication in 2023. Having two mechanistically distinct options — one an atypical antipsychotic, the other a glutamate modulator — gives prescribers flexibility to match treatment to individual patient profiles, particularly for those with cardiovascular comorbidities or sensitivity to antipsychotic side effects.

The commercial implications are substantial. Industry analysts have projected the agitation indication could meaningfully expand Auvelity's market beyond its original major depressive disorder approval. More importantly from a public health perspective, broader access to evidence-based treatment may reduce reliance on off-label antipsychotics in long-term care settings, where their use has been a persistent quality-of-care concern flagged by the Centers for Medicare and Medicaid Services.